Advertisement

Alpha-Synuclein as a Diagnostic Biomarker for Parkinson’s Disease

  • Joakim Bergström
  • Martin IngelssonEmail author
Protocol
Part of the Methods in Pharmacology and Toxicology book series (MIPT)

Abstract

The development of new biomarkers for Parkinson’s disease has been focused on the analyses of the α-synuclein protein in cerebrospinal fluid and plasma. Although significant differences in the levels of total α-synuclein have been found between patients and controls, none of these markers have been proven clinically useful as there has been a substantial overlap between the groups. Instead, assessment of toxic prefibrillar α-synuclein species has shown promising results, but further studies are needed to prove their diagnostic usefulness. In addition to analyses of body fluids, detection of α-synuclein in peripheral tissues—such as subcolonic mucosa and parotid gland—seem to offer novel interesting diagnostic possibilities.

Key words

ELISA α-Synuclein Plasma Cerebrospinal fluid Colon mucosa Parotid gland 

References

  1. 1.
    Irizarry MC, Growdon W, Gomez-Isla T et al (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 57(4):334–337CrossRefPubMedGoogle Scholar
  2. 2.
    Gómez-Tortosa E, Newell K, Irizarry M et al (1999) Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 53:1284–1291CrossRefPubMedGoogle Scholar
  3. 3.
    Jellinger KA (2014) Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Mov Disord 29(14):1720–1741CrossRefPubMedGoogle Scholar
  4. 4.
    McKeith IG (2000) Clinical Lewy body syndromes. Ann N Y Acad Sci 920:1–8CrossRefPubMedGoogle Scholar
  5. 5.
    Pereira JB, Svenningsson P, Weintraub D et al (2014) Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology 82(22):2017–2025CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Donaghy PC, McKeith IG (2014) The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther 6(4):46CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Fanciulli A, Wenning GK (2015) Multiple-system atrophy. N Engl J Med 372(3):249–263CrossRefPubMedGoogle Scholar
  8. 8.
    Ba F, Martin WR (2015) Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord 21(2):87–94CrossRefPubMedGoogle Scholar
  9. 9.
    Kasuga K, Nishizawa M, Ikeuchi T (2012) alpha-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. Int. J Alzheimers Dis 2012:437025Google Scholar
  10. 10.
    Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211CrossRefPubMedGoogle Scholar
  11. 11.
    Braak H, de Vos RA, Bohl J et al (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 396(1):67–72CrossRefPubMedGoogle Scholar
  12. 12.
    Holmqvist S, Chutna O, Bousset L et al (2014) Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 128(6):805–820CrossRefPubMedGoogle Scholar
  13. 13.
    Tokuda T, Salem SA, Allsop D et al (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem Biophys Res Commun 349(1):162–166CrossRefPubMedGoogle Scholar
  14. 14.
    Mollenhauer B, Cullen V, Kahn I et al (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213(2):315–325CrossRefPubMedGoogle Scholar
  15. 15.
    Mollenhauer B, Locascio JJ, Schulz-Schaeffer W et al (2011) alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10(3):230–240CrossRefPubMedGoogle Scholar
  16. 16.
    Wang Y, Shi M, Chung KA et al (2012) Phosphorylated alpha-synuclein in Parkinson’s disease. Sci Transl Med 4(121):121ra20PubMedPubMedCentralGoogle Scholar
  17. 17.
    Tateno F, Sakakibara R, Kawai T et al (2012) Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 26(3):213–216CrossRefPubMedGoogle Scholar
  18. 18.
    Parnetti L, Chiasserini D, Bellomo G et al (2011) Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson’s disease and degenerative dementias. Mov Disord 26(8):1428–1435CrossRefPubMedGoogle Scholar
  19. 19.
    Mollenhauer B, Trautmann E, Taylor P et al (2013) Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett 532:44–48CrossRefPubMedGoogle Scholar
  20. 20.
    Hong Z, Shi M, Chung KA et al (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133(Pt 3):713–726CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    van Dijk KD, Bidinosti M, Weiss A et al (2014) Reduced alpha-synuclein levels in cerebrospinal fluid in Parkinson’s disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol 21(3):388–394CrossRefPubMedGoogle Scholar
  22. 22.
    Shi M, Zhang J (2011) CSF alpha-synuclein, tau, and amyloid beta in Parkinson’s disease. Lancet Neurol 10(8):681, author’s reply 681-3CrossRefPubMedGoogle Scholar
  23. 23.
    van Geel WJ, Abdo WF, Melis R et al (2008) A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid. J Neurosci Methods 168(1):182–185CrossRefPubMedGoogle Scholar
  24. 24.
    Bidinosti M, Shimshek DR, Mollenhauer B et al (2012) Novel one-step immunoassays to quantify alpha-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem 287(40):33691–33705CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Li T, Holmes C, Sham PC, Vallada H, Birkett J, Kirov G, Lesch KP, Powell J, Lovestone S, Collier D (1997) Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset AD. Neuroreport 8:683–686CrossRefPubMedGoogle Scholar
  26. 26.
    Hall S, Ohrfelt A, Constantinescu R et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 69(11):1445–1452CrossRefPubMedGoogle Scholar
  27. 27.
    Kang JH, Irwin DJ, Chen-Plotkin AS et al (2013) Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70(10):1277–1287PubMedPubMedCentralGoogle Scholar
  28. 28.
    Mondello S, Constantinescu R, Zetterberg H et al (2014) CSF alpha-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders. Parkinsonism Relat Disord 20(4):382–387CrossRefPubMedGoogle Scholar
  29. 29.
    Parnetti L, Chiasserini D, Persichetti E et al (2014) Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease. Mov Disord 29(8):1019–1027CrossRefPubMedGoogle Scholar
  30. 30.
    Unterberger U, Lachmann I, Voigtlander T et al (2014) Detection of disease-associated alpha-synuclein in the cerebrospinal fluid: a feasibility study. Clin Neuropathol 33(5):329–334CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Buddhala C, Campbell MC, Perlmutter JS et al (2015) Correlation between decreased CSF alpha-synuclein and Abeta(1)(-)(4)(2) in Parkinson disease. Neurobiol Aging 36(1):476–484CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Aerts MB, Esselink RA, Abdo WF et al (2012) CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 33(2):430, e1-3CrossRefPubMedGoogle Scholar
  33. 33.
    Park MJ, Cheon SM, Bae HR et al (2011) Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson’s disease. J Clin Neurol 7(4):215–222CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Ohrfelt A, Grognet P, Andreasen N et al (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450(3):332–335CrossRefPubMedGoogle Scholar
  35. 35.
    Noguchi-Shinohara M, Tokuda T, Yoshita M et al (2009) CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer’s disease. Brain Res 1251:1–6CrossRefPubMedGoogle Scholar
  36. 36.
    Spies PE, Melis RJ, Sjogren MJ et al (2009) Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J Alzheimers Dis 16(2):363–369PubMedGoogle Scholar
  37. 37.
    Kasuga K, Tokutake T, Ishikawa A et al (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 81(6):608–610CrossRefPubMedGoogle Scholar
  38. 38.
    Reesink FE, Lemstra AW, van Dijk KD et al (2010) CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer’s disease. J Alzheimers Dis 22(1):87–95PubMedGoogle Scholar
  39. 39.
    Wennstrom M, Londos E, Minthon L et al (2012) Altered CSF orexin and alpha-synuclein levels in dementia patients. J Alzheimers Dis 29(1):125–132PubMedGoogle Scholar
  40. 40.
    Borghi R, Marchese R, Negro A et al (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson’s disease and normal subjects. Neurosci Lett 287(1):65–67CrossRefPubMedGoogle Scholar
  41. 41.
    Slaets S, Vanmechelen E, Le Bastard N et al (2014) Increased CSF alpha-synuclein levels in Alzheimer’s disease: correlation with tau levels. Alzheimers Dement 10(5 Suppl):S290–S298CrossRefPubMedGoogle Scholar
  42. 42.
    Compta Y, Valente T, Saura J et al (2015) Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson’s disease. J Neurol 262(2):294–306CrossRefPubMedGoogle Scholar
  43. 43.
    Magdalinou NK, Paterson RW, Schott JM et al (2015) A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 86(11):1240–1247CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Kapaki E, Paraskevas GP, Emmanouilidou E et al (2013) The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer’s disease. PLoS One 8(11):e81654CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Tokuda T, Qureshi MM, Ardah MT et al (2010) Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75(20):1766–1772CrossRefPubMedGoogle Scholar
  46. 46.
    Aasly JO, Johansen KK, Bronstad G et al (2014) Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front Aging Neurosci 6:248CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Hansson O, Hall S, Ohrfelt A et al (2014) Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther 6(3):25CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Jakowec MW, Petzinger GM, Sastry S et al (1998) The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson’s disease or normal controls. Neurosci Lett 253(1):13–16CrossRefPubMedGoogle Scholar
  49. 49.
    Giasson BI, Jakes R, Goedert M et al (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson’s disease. J Neurosci Res 59(4):528–533CrossRefPubMedGoogle Scholar
  50. 50.
    Barbour R, Kling K, Anderson JP et al (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5(2):55–59CrossRefPubMedGoogle Scholar
  51. 51.
    Kruse N, Persson S, Alcolea D et al (2015) Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiol Aging 36(9):2587–2596CrossRefPubMedGoogle Scholar
  52. 52.
    Foulds PG, Mitchell JD, Parker A et al (2011) Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson’s disease. FASEB J 25(12):4127–4137CrossRefPubMedGoogle Scholar
  53. 53.
    Gao L, Tang H, Nie K et al (2015) Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis. Int J Neurosci 125(9):645–654CrossRefPubMedGoogle Scholar
  54. 54.
    Sako W, Murakami N, Izumi Y et al (2014) Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Mov Disord 29(13):1599–1605CrossRefPubMedGoogle Scholar
  55. 55.
    Zetterberg H, Petzold M, Magdalinou N (2014) Cerebrospinal fluid alpha-synuclein levels in Parkinson’s disease--changed or unchanged? Eur J Neurol 21(3):365–367CrossRefPubMedGoogle Scholar
  56. 56.
    Winner B, Jappelli R, Maji SK et al (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108(10):4194–4199CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Rockenstein E, Nuber S, Overk CR et al (2014) Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 137(Pt 5):1496–1513CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Sierks MR, Chatterjee G, McGraw C et al (2011) CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb) 3(12):1188–1196CrossRefGoogle Scholar
  59. 59.
    Brannstrom K, Lindhagen-Persson M, Gharibyan AL et al (2014) A generic method for design of oligomer-specific antibodies. PLoS One 9(3), e90857CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Lesage S, Brice A (2009) Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18(R1):R48–R59CrossRefPubMedGoogle Scholar
  61. 61.
    Schmid AW, Fauvet B, Moniatte M et al (2013) Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics 12(12):3543–3558CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Fujiwara H, Hasegawa M, Dohmae N et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4(2):160–164PubMedGoogle Scholar
  63. 63.
    Stewart T, Sossi V, Aasly JO et al (2015) Phosphorylated alpha-synuclein in Parkinson’s disease: correlation depends on disease severity. Acta Neuropathol Commun 3:7CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Wennstrom M, Surova Y, Hall S et al (2013) Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 8(1), e53250CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    El-Agnaf OM, Salem SA, Paleologou KE et al (2003) Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J 17(13):1945–1947PubMedGoogle Scholar
  66. 66.
    El-Agnaf OM, Salem SA, Paleologou KE et al (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J 20(3):419–425CrossRefPubMedGoogle Scholar
  67. 67.
    Lee PH, Lee G, Park HJ et al (2006) The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J Neural Transm 113(10):1435–1439CrossRefPubMedGoogle Scholar
  68. 68.
    Duran R, Barrero FJ, Morales B et al (2010) Plasma alpha-synuclein in patients with Parkinson’s disease with and without treatment. Mov Disord 25(4):489–493CrossRefPubMedGoogle Scholar
  69. 69.
    Foulds PG, Diggle P, Mitchell JD et al (2013) A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson’s disease. Sci Rep 3:2540CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Li QX, Mok SS, Laughton KM et al (2007) Plasma alpha-synuclein is decreased in subjects with Parkinson’s disease. Exp Neurol 204(2):583–588CrossRefPubMedGoogle Scholar
  71. 71.
    Laske C, Fallgatter AJ, Stransky E et al (2011) Decreased alpha-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer’s disease patients and control subjects. Dement Geriatr Cogn Disord 31(6):413–416CrossRefPubMedGoogle Scholar
  72. 72.
    Gorostidi A, Bergareche A, Ruiz-Martinez J et al (2012) Alphalpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS One 7(12), e52312CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Shi M, Zabetian CP, Hancock AM et al (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease. Neurosci Lett 480(1):78–82CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Mata IF, Shi M, Agarwal P et al (2010) SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 67(11):1350–1356CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Besong-Agbo D, Wolf E, Jessen F et al (2013) Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80(2):169–175CrossRefPubMedGoogle Scholar
  76. 76.
    Smith LM, Schiess MC, Coffey MP et al (2012) Alpha-Synuclein and anti-alpha-synuclein antibodies in Parkinson’s disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. PLoS One 7(12):e52285CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Malek N, Swallow D, Grosset KA et al (2014) Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson’s disease—a systematic review. Acta Neurol Scand 130(2):59–72CrossRefPubMedGoogle Scholar
  78. 78.
    Shi M, Liu C, Cook TJ et al (2014) Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol 128(5):639–650CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Devic I, Hwang H, Edgar JS et al (2011) Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain 134(Pt 7), e178CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Beach TG, Adler CH, Sue LI et al (2010) Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119(6):689–702CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Lebouvier T, Chaumette T, Damier P et al (2008) Pathological lesions in colonic biopsies during Parkinson’s disease. Gut 57(12):1741–1743CrossRefPubMedGoogle Scholar
  82. 82.
    Lebouvier T, Neunlist M, Bruley S (2010) des Varannes, et al., Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS One 5(9), e12728CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Shannon KM, Keshavarzian A, Mutlu E et al (2012) Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov Disord 27(6):709–715CrossRefPubMedGoogle Scholar
  84. 84.
    Pouclet H, Lebouvier T, Coron E et al (2012) A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson’s disease. Neurobiol Dis 45(1):305–309CrossRefPubMedGoogle Scholar
  85. 85.
    Pouclet H, Lebouvier T, Coron E et al (2012) A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson’s disease. Neurogastroenterol Motil 24(4):e202–e205CrossRefPubMedGoogle Scholar
  86. 86.
    Pouclet H, Lebouvier T, Coron E et al (2012) Lewy pathology in gastric and duodenal biopsies in Parkinson’s Disease. Mov Disord 27(6):708CrossRefPubMedGoogle Scholar
  87. 87.
    Sanchez-Ferro A, Rabano A, Catalan MJ et al (2015) In vivo gastric detection of alpha-synuclein inclusions in Parkinson’s disease. Mov Disord 30(4):517–524CrossRefPubMedGoogle Scholar
  88. 88.
    Beach TG, Adler CH, Dugger BN et al (2013) Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 72(2):130–136CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Del Tredici K, Hawkes CH, Ghebremedhin E et al (2010) Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 119(6):703–713CrossRefPubMedGoogle Scholar
  90. 90.
    Donadio V, Incensi A, Leta V et al (2014) Skin nerve alpha-synuclein deposits: a biomarker for idiopathic Parkinson disease. Neurology 82(15):1362–1369CrossRefPubMedGoogle Scholar
  91. 91.
    Mu L, Sobotka S, Chen J et al (2013) Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol 72(2):119–129CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Public Health & Caring Sciences/GeriatricsUppsala UniversityUppsalaSweden

Personalised recommendations